Clinical trial
Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With Moderate to Severe Systemic Lupus Erythematosus
NCT00137969 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With Moderate to Severe Systemic Lupus Erythematosus
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- May 10, 2005
- Completion date
- August 25, 2008
- Enrollment
- 262 (actual)
- Sites
- 65
Conditions
As the registry lists them; a condition with its own page is linked.